Table 4

Logistic regression analysis of the factors associated with hospitalisation in patients with rheumatic disease and COVID-19

VariablesP valueOR (95% CI)
Treatment of the rheumatic disease
 Treatment (csDMARDs)
 ts/bDMARDs0.1530.549 (0.242 to 1.249)
 bDMARDs
 TNF inhibitors0.0180.320 (0.125 to 0.821)
 IL-17-inhibitors0.3990.472 (0.082 to 2.701)
 Anti-CD200.0734.849 (0.863 to 27.249)
 Anti-BAFF0.7960.529 (0.004 to 66.128)
 IL-6 inhibitors0.2940.400 (0.072 to 2.217)
 Others0.6790.741 (0.180 to 3.057)
 tsDMARDs0.8300.869 (0.241 to 3.130)
 Glucocorticoids (no)0.1641.692 (0.807 to 3.546)
Demographics
 Age<0.0011.053 (1.024 to 1.082)
 Sex (female)0.0432.310 (1.025 to 5.207)
Comorbidities
 COPD (no)0.0546.639 (0.968 to 45.542)
 Overweight/obesity (no)0.0392.222 (1.043 to 4.733)
 Chronic liver disease (no)0.0455.003 (1.036 to 24.161)
COVID-19 symptoms
 Fever (no)<0.0016.093 (2.673 to 13.887)
 Cough (no)0.0891.896 (0.908 to 3.959)
 Sore throat (no)0.0030.210 (0.074 to 0.595)
 Dyspnoea (no)<0.00111.515 (5.453 to 24.316)
 Arthralgia (no)0.0010.183 (0.068 to 0.497)
 Nausea (no)0.0024.379 (1.708 to 11.225)
 Asthaenia (no)0.0282.263 (1.092 to 4.687)
Disease-related factors
 Diagnosis (RA)
 Spondyloarthropathies0.5080.719 (0.270 to 1.912)
 Systemic lupus erythematosus0.1760.401 (0.107 to 1.509)
 Other rheumatic diseases0.2570.465 (0.124 to 1.744)
  • bDMARD, biological disease-modifying antirheumatic drugs; COPD, chronic obstructive pulmonary disease; csDMARD, conventional synthetic disease-modifying antirheumatic drugs; ICU, intensive care unit; IL, interleukin; RA, rheumatoid arthritis; TNF, tumour necrosis factor; tsDMARD, targeted synthetic disease-modifying antirheumatic drugs.